Disclosures

Disclosures - Seventh Edition

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Society of Hematology must ensure balance, independence, objectivity, and scientific rigor in all of the educational activities it sponsors. All authors are expected to disclose any financial relationships with any proprietary entity producing health care goods or services that have occurred within 24 months from the start of or during the production of the work and that are relevant to the author’s content. If an author has such a financial interest, then she or he must disclose the name of the commercial interest and nature of the relationship (eg, consultant, grantee, etc.). An author who has no such financial relationship must declare that she or he has nothing to disclose. The intent of this disclosure is not to prevent an author with a significant financial or other relationship from making a presentation, but rather to provide readers with information that they can use to make their own judgments. It remains for the audience to determine whether the author’s interests or relationships may influence the work with regard to exposition or conclusion.

Disclosures of financial relationships

Tanja A. Gruber: no competing financial interest. Omar Abdel-Wahab: no competing financial interest.

Nathan T. Connell: membership on Board of Directors: The Michael H. Flanagan Foundation. Shannon L. Carpenter: consultant: CSL Behring, Kedrion Biopharmaceuticals, HEMA Biologics, Novo Nordisk Pharmaceuticals, Inc., Bayer, Genentech; membership on Board of Directors: Hemostasis Thrombosis Research Society, American Thrombosis and Hemostasis Network; grant funding: Shire, CSL Behring.

Peter A Kouides: coprincipal investigator for Octapharma-sponsored, investigator-initiated trial in postpartum hemorrhage; member of the National Blood Clot Alliance Medical & Scientific Advisory Board; member of the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation; a member of the Medical Advisory Committee of the Foundation for Women and Girls with Blood Disorders. Michael Paidas: research funding from CSL Behring as principal investigator for postpartum hemorrhage associated with placenta accreta treatment trial; has received research funding from rEVO Biologics and was principal investigator for a preterm preeclampsia treatment trial; receives research funding from BioIncept LLC; receives grant funding from GestVision as a principal investigator for a preeclampsia prediction study; receives grant funding from Progenity as a principal investigator for a preeclampsia prediction study; member of Scientific Advisory Board of BioIncept LLC and has stock options; member of the Medical and Scientific Advisory Council of the National Hemophilia Foundation; member of the Medical Advisory Committee of the Foundation for Women and Girls with Blood Disorders.

Alan E. Lichtin: no competing financial interest. Vinay Prasad: royalties from his book Ending Medical Reversal; funding from the Laura and John Arnold Foundation; honoraria for grand rounds/lectures from several universities, medical centers, and professional societies; writer for Medscape.

Heather A. Leitch: honoraria from, research funding from, and/or service on advisory boards for AbbVie, Alexion, ApoPharma, Celgene, and Novartis; member of the Exjade Speaker’s Bureau. Elizabeta Nemeth: stockholder of Intrinsic LifeSciences and Silarus Therapeutics; consultant for La Jolla Pharmaceutical Company, Protagonist Therapeutics, and Keryx Biopharmaceuticals.

Mohandas Narla: no competing financial interest. Jacquelyn M. Powers: no competing financial interest.

Farzana Sayani: research funding: Celgene. Payal Desai: research funding: Pfizer, Prolong. Sophie Lanzkron: research funding: Pfizer, Global Blood Therapeutics, Prolong.

Ronald S. Go: no competing financial interest. Kevin H. M. Kuo: consultancy: Agios, Alexion, Celgene, and Novartis; member of scientific advisory board: Agios and Novartis; honoraria: Alexion and Novartis; scientific collaboration: Abferom and Phoenicia Biosciences.

Saskia Middeldorp: consulting fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Sanofi, and Daiichi Sankyo; research support from GlaxoSmithKline, Aspen, the alliance of Bristol-Myers Squibb and Pfizer, and Sanquin Blood Supply. Paul Monagle: steering committees: Bayer and Bristol-Myers Squibb; research support: Diagnostica Stago. Ted Wun: steering committees and research support: Janssen and Pfizer.

Riten Kumar: consultancy: CSL Behring and Bayer; research support: HTRS MRA supported by an educational grant by Bioverativ Therapeutics. Christine L. Kempton: consultancy: Genentech, Shire, Novo Nordisk, Bayer Healthcare; honoraria: Grifols; research support: Novo Nordisk.

Michele Lambert: membership on a board or advisory committee: Bayer; consultancy: Dynamed and Shionogi; honoraria and membership on a board or advisory committee: Novartis. Adam Cuker: consultancy and research funding: Bioverativ; consultancy: Genzyme, Stago, and Synergy; membership on a board or advisory committee: Kedrion; research funding: Novo Nordisk and Spark Therapeutics. Andreas Greinacher: consultancy: Aspen, Bristol-Myers Squibb, and Merck Sharp & Dohme; consultancy and honoraria: Macopharma and MSD Sharp & Dohme GmbH.

Tracy I. George: consultancy: Roche. Anne M. Winkler: employment: Instrumentation Laboratory.

William Savage: full-time employment: Takeda Pharmaceutical Company. Stella T. Chou: no competing financial interest.

Irum Khan: no competing financial interest. Kim-Hien T. Dao: no competing financial interest.

Matthew J. Wieduwilt: research funding: Sigma-Tau. Roland B. Walter: membership on a board or advisory committee: Amphivena Therapeutics; consultancy and research funding: Aptevo Therapeutics and Covagen; consultancy: BioLineRx, Jazz Pharmaceuticals, and Race Oncology: research funding: Seattle Genetics.

Alison A. Bertuch: research funding: National Institutes of Health. Cynthia E. Dunbar: research funding: intramural program of the National Heart, Lung, and Blood Institute; cooperative research and development agreement: Novartis.

Vivian G. Oehler: research funding: Pfizer. Jane F. Apperley: research funding: Ariad, Incyte, Pfizer; membership on advisory boards: Incyte, Pfizer, and Novartis.

Brady L. Stein: membership on scientific advisory board: Incyte. Aaron T. Gerds: membership on advisory board: Incyte.

Amy E. DeZern: no competing financial interest. Catherine Smith: no competing financial interest.

Eytan M. Stein: advisory boards: Celgene, Agios, Novartis, Astellas, Bayer, and Pfizer. Neerav Shukla: no competing financial interest. Jessica K. Altman: advisory boards: AbbVie, Agios, Astellas, Daiichi Sankyo, Novartis, and Theradex; data monitoring committee for Glycomimetics.

Oliver G. Ottmann: research funding: Incyte. Mats Heyman: no competing financial interest.

Pamela B. Allen: research advisory board (with honorarium): Bayer. Andrew M. Evens: research advisory boards (with honoraria): Affimed, Janssen, Acerta, Bayer, AbbVie, and Novartis; research funding: Seattle Genetics and Tesaro.

Jeremy S. Abramson: Consultancy: AbbVie, Amgen, Celgene, Genentech, Gilead, Janssen, Juno Therapeutics, Kite Pharma, Karyopharm, Merck, Novartis, Verastem, and Seattle Genetics. David T. Yang: no competing financial interest.

Tanya Siddiqi: speaker for ibrutinib (Pharmacyclics/Janssen) and brentuximab vedotin (Seattle Genetics); consultancy: Juno Therapeutics, AstraZeneca, Pharmacyclics, and BeiGene. Steven Coutre: consultancy: Pharmacyclics, Janssen, Gilead, AbbVie, and Novartis.

Michaela Liedtke: consultancy: Prothena, Pfizer, Amgen, Caelum, and Takeda; research funding: Celgene, Takeda, Amgen, Pfizer, Prothena, Gilead, BlueBirdBio, and Genentech/Roche. Rafael Fonseca: consultancy: Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Merck, Juno, Kite, Aduro, and AbbVie; member of scientific advisory board: Adaptive Biotechnologies.

Discussion of off-label drug use

Not applicable.

Nathan T. Connell and Shannon L. Carpenter: corticosteroids and rituximab for use in thrombotic thrombocytopenic purpura; antithrombin III and activated protein C for disseminated intravascular coagulation; cyclophosphamide, corticosteroids, intravenous immunoglobulin (IVIG), and rituximab for catastrophic antiphospholipid antibody syndrome; corticosteroids, intravenous immunoglobulin, rituximab, and thrombopoietin receptor agonists for pediatric immune thrombocytopenia (ITP); rituximab for adult ITP and thrombotic thrombocytopenic purpura; granulocyte colony-stimulating factor outside of severe congenital neutropenia; desmopressin for use in platelet function disorders; desmopressin, recombinant factor VIIa, prothrombin complex concentrate, activated prothrombin complex concentrate, fibrin glue, ε-aminocaproic acid, and tranexamic acid for use in surgical bleeding and reversal of direct oral anticoagulants; IVIG for posttransfusion purpura; IVIG for drug- induced ITP; conjugated estrogens for use in uremic bleeding; hemoglobin-based oxygen carriers for anemia in patients who refuse blood products; IVIG and erythropoietin for use in parvovirus-associated pure red cell aplasia; angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for use in post–renal transplant erythrocytosis; rituximab for use in CD20⁺ posttransplant lymphoproliferative disorders.

Peter A. Kouides: clotting factor concentrates (plasma and recombinant), cyclosporine, desmopressin, eculizumab, eltrombopag, erythropoietin, gamma globulin, romiplostim, and tranexamic acid in pregnancy. Michael Paidas: aspirin, fondaparinux, low-molecular-weight heparin, and warfarin in pregnancy.

Alan E. Lichtin: epoetin alfa and darbepoetin alfa in myelodysplastic syndromes.

Heather A. Leitch and Elizabeta Nemeth: off-label use of iron chelation therapy.

Not applicable.

Not applicable.

Ronald S. Go and Kevin H. M. Kuo: azathioprine, chlorambucil, cyclophosphamide, cyclosporine, danazol, intravenous immunoglobulin, mycophenolate mofetil, and rituximab in the treatment of autoimmune hemolytic anemia.

Not applicable.

Riten Kumar and Christine L. Kempton: recombinant factor VIIa for management of bleeding in hemophilia at doses and regimens that are not approved and for other off-label indications; prothrombin complex concentrates for treatment of factor II and X deficiency.

Michele Lambert, Adam Cuker, and Andreas Greinacher: desmopressin for inherited platelet function defects and uremic platelets; recombinant factor VIIa for inherited platelet function defects; rituximab for immune thrombocytopenia and thrombotic thrombocytopenic purpura; fondaparinux, bivalirudin, and direct oral anticoagulants for heparin-induced thrombocytopenia.

Not applicable.

Not applicable.

Not applicable.

Matthew J. Wieduwilt and Roland B. Walter: drug and cellular therapy for hematologic malignancies and hematopoietic cell transplantation.

Alison A. Bertuch and Cynthia E. Dunbar: androgens (eg, oxymetholone or danazol) in Fanconi anemia and telomeropathies; granulocyte colony-stimulating factor in nonsevere congenital neutropenia; glucocorticoids in Diamond-Blackfan anemia, autoimmune neutropenias, and macrophage activation syndrome; iron chelating agents in congenital dyserythropoietic anemias; interferon-α in congenital dyserythropoietic anemia type I and Erdheim-Chester disease; plerixafor in WHIM syndrome; intravenous immunoglobin in autoimmune neutropenias; interferon-γ in chronic granulomatous disease; colchicine in familial Mediterranean fever; anakinra in Majeed syndrome; etoposide, methotrexate, cyclosporine, antithymocyte globulin, and dexamethasone in hemophagocytic lymphohistiocytosis; topical steroids, nitrogen mustard, and psoralen in Langerhans cell histiocytosis; vinblastine, methotrexate, and glucocorticoids in Langerhans cell histiocytosis.

Not applicable.

Brady L. Stein and Aaron T. Gerds: interferon for myeloproliferative neoplasms.

Amy E. DeZern: cyclosporine, rabbit antithymocyte globulin, alemtuzumab, cyclophosphamide. Catherine Smith: deferoxamine, deferasirox, deferiprone, epoetin, darbepoetin, filgrastim, tbo-filgrastim, sargramostim, molgramostim, pegfilgrastim, romiplostim, eltrombopag, and clofarabine.

Not applicable.

Oliver G. Ottmann and Mats Heyman: blinatumomab, dasatinib, ponatinib, ruxolitinib, and bortezomib.

Pamela B. Allen and Andrew M. Evens: rituximab for the treatment of lymphocyte-predominant Hodgkin lymphoma; histone deacetylase inhibitor and lenalidomide in relapsed/refractory Hodgkin lymphoma.

Jeremy S. Abramson and David T. Yang: lenalidomide in follicular lymphoma; rituximab in hairy cell leukemia; bendamustine, brentuximab vedotin, gemcitabine, ibrutinib, lenalidomide, and oxaliplatin in diffuse large B-cell lymphoma; ibrutinib, lenalidomide, temozolomide and thiotepa in primary central nervous system lymphoma; pembrolizumab in primary mediastinal large B-cell lymphoma; alemtuzumab, gemcitabine, lenalidomide, and liposomal doxorubicin in peripheral T-cell lymphoma; mogamulizumab in adult T-cell lymphoma/leukemia; crizotinib in anaplastic lymphoma kinase–positive anaplastic large-cell lymphoma.

Tanya Siddiqi and Steven Coutre: chimeric antigen receptor (CAR) T cells.

Michaela Liedtke and Rafael Fonseca: multiple drugs and combinations.

Disclosures - Sixth Edition

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Society of Hematology must ensure balance, independence, objectivity, and scientific rigor in all of the educational ac- tivities it sponsors. All authors are expected to disclose any financial relationships with any proprietary entity producing health care goods or services that have occurred within 24 months from the start of or during the production of the work and that are relevant to the author’s content. If an au- thor has such a financial interest, then she or he must dis- close the name of the commercial interest and nature of the relationship (eg, consultant, grantee, etc.). An author who has no such financial relationship must declare that she or he has nothing to disclose. The intent of this disclosure is not to prevent an author with a significant financial or other relationship from making a presentation, but rather to pro- vide readers with information that they can use to make their own judgments. It remains for the audience to determine whether the author’s interests or relationships may influence the work with regard to exposition or conclusion.

Click here to view the disclosures as a PDF

Disclosures of financial relationships

Chapter 1, Molecular basis of hematology
Laura Schuettpelz declares no competing financial interest. Omar Abdel-Wahab declares no competing financial interest.

Chapter 2, Consultative hematology I:hospital-based and selected outpatient topics
Cindy Neunert: safety advisory board: Genzyme. Anita Rajasekhar: consultancy: Alexion, Octapharma, Bayer, Baxter; funding: American Society of Hematology.

Chapter 3, Consultative hematology II: women’s health issues
Margaret V. Ragni: research support from Alnylam, ATHN, Baxalta, Biogen, CSL Behring, Dimension, Genentech Roche, Novo Nordisk, Novartis, Opko, Pfizer, Shire, SPARK, and Vascular Medicine Institute; consultant for Baxter , Bio-Marin, Biogen, Medscape, Opko, Tacere Therapeutics; member of the National Hemophilia Foundation Medical &Scientific Advisory Committee and a member of the Foundation for Women and Girls with Blood Disorders Advisory Board. Peter A. Kouides: consultant for Baxter, CSL Behring, Grifols; member of the National Blood Clot Alliance Medical& Scientific Advisory Board. Sarah H. O’Brien: research support from Bayer and the Hemophilia Thrombosis and Hemostasis Research Society of North America (HTRS); member of an advisory board for GlaxoSmithKline.

Chapter 4, Hematopoietic growth factors
Aaron T. Gerds declares no competing financial interest. Alan E. Lichtin declares no competing financial interest.

Chapter 5, Iron metabolism, iron overload, and the porphyrias
Heather A. Leitch has received honoraria, research funding, and/or served on advisory boards for Alexion, Apo-Pharma, Celgene, and Novartis. She is a member of the Exjade speakers’ bureau. Jecko Thachil declares no competing financial interest.

Chapter 6, Acquired underproduction anemias
Siobán B. Keel declares no competing financial interest. Narla Mohandas declares no competing financial interest.

Chapter 7, Hemolytic anemias
Farzana A. Sayani declares no competing financial interest. Sophie Lanzkron: research funding: Novartis, Glycomimetics, Emmaus.

Chapter 8, Thrombosis and thrombophilia
David Garcia: consultancy: Bristol-Myers Squibb, Portola, Pfizer, Boehringer Ingelheim, and Daiichi Sankyo. Saskia Middeldorp: consulting fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Daiichi Sankyo and research support from GlaxoSmithKline, Aspen, the allianceof Bristol-Myers Squibb and Pfizer, and Sanquin Blood Supply. Anjali Alatkar Sharathkumar: consulting fees from Baxter, CSL Behring, and Biogen Idec.

Chapter 9, Bleeding disorders
Christine L. Kempton: consultancy: Baxter Healthcare, BiogenIdec, Kedrion Biopharma; research support: Novo Nordisk. Jorge A. Di Paola: Consultancy: CSL Behring; DSMB Pfizer.

Chapter 10, Disorders of platelet number and function
Adam Cuker: consultancy: Amgen, Bracco, Genzyme; research support: Diagnostica Stago, T2 Biosystems. Andreas Greinacher: consultancy: Bayer Healthcare, Boehringer Ingelheim, ASPEN, Instrumentation Laboratory; honoraria: Bristol Myers Squibb.

Chapter 11, Laboratory hematology
John L. Frater declares no competing financial interest. Anne M. Winkler declares no competing financial interest.

Chapter 12, Transfusion medicine
William Savage received research funding from Fresenius-Kabi. Suzanne Bakdash declares no competing financial interest.

Chapter 13, Cellular basis of hematopoiesis and stem cell transplantation
Paresh Vyas declares no competing financial interest. Aly Karsan declares no competing financial interest.

Chapter 14, Clinical hematopoietic cell transplantation
Matthew Wieduwilt: research funding: Sigma Tau. SergioA. Giralt: consultancy: Celgene; research funding: Celgene; Sanofi-Aventis; Honoraria: Celgene, Millennium, Sanofi-Aventis; speakers’ bureau: Sanofi-Aventis.

Chapter 15, Myeloid disorders and inherited marrow failure syndromes
Alison A. Bertuch: research funding: Cancer Prevention Research Institute of Texas, National Institutes of Health, American Society of Hematology. Inderjeet Dokal: research funding: MRC, Children with Cancer, Leukaemia & Lymphoma Research.

Chapter 16, Chronic myeloid leukemia and myeloproliferative neoplasms
Ruben A. Mesa: consulting: Novartis; research support: Incyte, Gilead, Genentech, CTI, Promedior, and NS Pharma. BradyL. Stein: advisory board/consulting for Incyte Corporation.

Chapter 17, Acquired marrow failure syndromes: aplastic anemia, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromes
Phillip Scheinberg: speaker: Novartis. Amy E. DeZern: no competing financial interest. David P. Steensma: advisory board: Incyte, Novartis, Celgene, MEI Pharma, Takeda, and Genoptix.

Chapter 18, Acute myeloid leukemia
B. Douglas Smith declares no competing financial interest. Eytan M. Stein declares no competing financial interest.

Chapter 19, Acute lymphoblastic leukemia and lymphoblastic lymphoma
Mark R. Litzow: research funding from Amgen. Mats Heyman: no competing financial interest.

Chapter 20, Hodgkin lymphoma
Ann S. LaCasce: research funding: Seattle Genetics. AndreasEngert: consultancy, presentation, and research funding: Takeda and Millennium.

Chapter 21, Non-Hodgkin lymphoma
Brad Kahl: research support: Genentech and AbbVie; consultancy: Celgene, Roche, Seattle Genetics, Millennium, Infinity, and Cell Therapeutics. Greg Nowakowski: research support: Celgene and Bayer; consultancy: Celgene, Bayer, and Seattle Genetics. David Yang: no competing financial interest.

Chapter 22, Chronic lymphocytic leukemia/small lymphocytic lymphoma
Clive S. Zent: research funding from Novartis, Biothera, GlaxoSmithKline, Genzyme, and Genentech. Timothy G. Call: no conflicts of interest to declare.

Chapter 23, Plasma cell disorders
Shaji K. Kumar: consultancy: Celgene, Millennium, Onyx, Janssen, Bristol-Myers Squibb, Sanofi, and Skyline Diagnostics; research funding: Celgene, Millennium, Onyx, Janssen, Bristol-Myers Squibb, Sanofi, and Novartis. Jesús San Miguel: consultancy: Janssen, Novartis, Celgene, Millennium, Onyx, Bristol-Myers Squibb, and Sanofi.

Discussion of off-label drug use

In compliance with ACCME policy, the American Society of Hematology requires all authors to disclose any discussion of off-label drug use in their chapters.

Chapter 1, Molecular basis of hematology
No discussion of off-label drug use.

Chapter 2, Consultative hematology I: hospital-based and selected outpatient topics Cindy Neunert: corticosteroids and rituximab for use in thrombotic thrombocytopenic purpura; antithrombin III and activated protein C for disseminated intravascular coagulation; cyclophosphamide, corticosteroids, intravenous immunoglobulin, and rituximab for catastrophic antiphospholipid antibody syndrome; corticosteroids, intravenous immunoglobulin, rituximab, and thrombopoietin receptor agonists for pediatric immune thrombocytopenia (ITP); rituximab for adult ITP; and granulocyte-stimulating factor outside of severe congenital neutropenia. Anita Rajasekhar: desmopressin for use in platelet function disorders; desmopressin, recombinant factor VIIa, prothrombin complex concentrate, activated prothrombin complex concentrate, fibrin glue, and, ε-aminocaproic acid, and tranexamic acid for use in surgical bleeding; conjugated estrogens for use in uremic bleeding; intravenous immunoglobulin and erythropoietin for use in parvovirus-associated pure red cell aplasia; angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for use in post–renal transplant erythrocytosis; and rituximab for use in CD20+ posttransplant lymphoproliferative disorder.

Chapter 3, Consultative hematology II: women’s health issues 
Margaret V. Ragni: not applicable. Peter A. Kouides: lowmolecular- weight heparin, fondaparinux, aspirin, and warfarin in pregnancy. Sarah H. O’Brien: not applicable.

Chapter 4, Hematopoietic growth factors 
Aaron T. Gerds: filgrastim in HIV. Alan E. Lichtin: epoetin alfa and darbepoetin alfa in myelodysplastic syndromes.

Chapter 5, Iron metabolism, iron overload, and the porphyrias 
Off-label use of iron chelation therapy.

Chapter 6, Acquired underproduction anemias 
No discussion of off-label drug use.

Chapter 7, Hemolytic anemias 
Rituximab, cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine, and danazol in the treatment of autoimmune hemolytic anemia.

Chapter 8, Thrombosis and thrombophilia
No discussion of off-label drug use.

Chapter 9, Bleeding disorders
Recombinant factor VIIa for management of bleeding in hemophilia at doses and regimens that are not approved and for other off-label indications, as well as prothrombin complex concentrates for treatment of factor II and X deficiency.

Chapter 10, Disorders of platelet number and function
Desmopressin for inherited platelet function defects and uremic platelets, recombinant factor VIIa for inherited platelet function defects, rituximab for immune thrombocytopenia and thrombotic thrombocytopenic purpura, and fondaparinux and bivalirudin for heparin-induced thrombocytopenia.

Chapter 11, Laboratory hematology
No discussion of off-label drug use.

Chapter 12, Transfusion medicine
No discussion of off-label drug use.

Chapter 13, Cellular basis of hematopoiesis and stem cell transplantation
No discussion of off-label drug use.

Chapter 14, Clinical hematopoietic cell transplantation
Matthew Wieduwilt and Sergio A. Giralt: drug therapy for hematologic malignancies and hematopoietic cell transplantation.

Chapter 15, Myeloid disorders and inherited marrow failure syndromes
No discussion of off-label drug use.

Chapter 16, Chronic myeloid leukemia and myeloproliferative neoplasms
No discussion of off-label drug use.

Chapter 17, Acquired marrow failure syndromes: aplastic anemia, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromes 
Phillip Scheinberg: cyclosporine, rabbit antithymocyte globulin, alemtuzumab, and cyclophosphamide. Amy E. DeZern: not applicable. David P. Steensma: eltrombopag, romiplostim, lenalidomide for non-del5q, darbepoetin, and epoetin.

Chapter 18, Acute myeloid leukemia
No discussion of off-label drug use.

Chapter 19, Acute lymphoblastic leukemia and lymphoblastic lymphoma
Mark R. Litzow and Mats Heyman: blinatumomab, dasatinib, and ponatinib.

Chapter 20, Hodgkin lymphoma
Ann S. LaCasce: rituximab for the treatment of lymphocytepredominant Hodgkin lymphoma. Andreas Engert: not applicable.

Chapter 21, Non-Hodgkin lymphoma
No discussion of off-label drug use.

Chapter 22, Chronic lymphocytic leukemia/small lymphocytic lymphoma
Idelalisib, ibrutinib, ofatumumab, pentostatin, and cladribine.

Chapter 23, Plasma cell disorders
No discussion of off-label drug use.